NTRK1 and cancer: The use of targeted cancer agents such as tyrosine kinase inhibitors against oncogenic receptor tyrosine kinases, or immunotherapies such as the anti-PD1 biologics, typically rely on the determination of the presence of the drug target, as assessed by immunohistochemistry, mRNA expression, or DNA sequencing, as a prerequisite for treating cancer patients with those targeted therapies.